Positive Phase III readout for Baremsis

UK-based Acacia Pharma (Euronext: ACPH) says that positive results from a Phase III study of Baremsis (amisulpride injection) as a treatment for established post-operative nausea and vomiting (PONV) have been published in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA) ( Kranke et al.). Positive headline results were first announced by the Company in January 2016.

The Phase III trial demonstrated that Baremsis is safe and resulted in a statistically-significant reduction in the emergence of PONV when given in combination with an antiemetic drug from another class to adult patients undergoing elective procedures who are at high risk of PONV.

Acacia Pharma said earlier this month that it had priced its initial public offering on the Brussels stock exchange, raising 40 million euros ($49.09 million), and its shares gained 3.4% to 3.58 euros this morning.